Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available ...

The biotech’s pipeline features bispecifics against a range of targets, including one candidate that hits PD-L1 and TGFβ and ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Read More on ITOS: ...

Among its late-stage pipelines, we assign a very low probability of 10% to its phase 3 project on Ociperlimab, an anti-TIGIT antibody, after Roche failed its TIGIT pivotal trial in July 2024. Hence, ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

That efficacy exceeded iTeos’ expectations and was backed by a safety profile “in line with the TIGIT:PD-1 class,” said the company. Protein degrader specialist Lycia Therapeutics completed ...

Dr. Cohen-Dayag added, "Our partner, AstraZeneca, continued to advance development of rilvegostoming, their PD-1/TIGIT bispecific of which the TIGIT component is derived from COM902. In September 2024 ...

Arcus Biosciences (NYSE:RCUS – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at ...